NewAmsterdam Pharma Co NV (NAMS)
16.23
+0.40
(+2.53%)
USD |
NASDAQ |
Sep 27, 16:00
16.26
+0.04
(+0.22%)
After-Hours: 20:00
NewAmsterdam Pharma Cash from Financing (Quarterly): 4.658M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 4.658M |
March 31, 2024 | 198.18M |
Date | Value |
---|---|
June 30, 2023 | 6.334M |
March 31, 2023 | 2.392M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
2.392M
Minimum
Mar 2023
198.18M
Maximum
Mar 2024
52.89M
Average
5.496M
Median
Cash from Financing (Quarterly) Benchmarks
Koninklijke Philips NV | -- |
uniQure NV | 0.05M |
ProQR Therapeutics NV | -0.2997M |
Merus NV | 444.90M |
argenx SE | 40.07M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -53.98M |
Cash from Investing (Quarterly) | -0.209M |
Free Cash Flow | -170.36M |
Free Cash Flow Per Share (Quarterly) | -0.5721 |
Free Cash Flow to Equity (Quarterly) | -54.19M |
Free Cash Flow to Firm (Quarterly) | -54.19M |
Free Cash Flow Yield | -12.11% |